Table 3 Summary of clinical response from baseline to week 24
| Â | Treatment group | Low Ki subgroup | High Ki subgroup | |||
|---|---|---|---|---|---|---|
Chemotherapy arm (n = 87) | Endocrine therapy arm (n = 87) | Chemotherapy arm (n = 49) | Endocrine therapy arm (n = 48) | Chemotherapy arm (n = 36) | Endocrine therapy arm (n = 37) | |
Best overall tumour response | ||||||
 MRI | ||||||
  CR | 14 (16.3%) | 2 (2.3%) | 6 (12.2%) | 1 (2.1%) | 7 (19.4%) | 1 (2.7%) |
  PR | 58 (67.4%) | 43 (50.6%) | 35 (71.4%) | 28 (58.3%) | 22 (61.1%) | 14 (37.8%) |
  CR + PR | 72 (83.7) | 45 (52.9%) | 41 (83.7%) | 29 (60.4%) | 29 (81.1%) | 15 (40.5%) |
 Calliper | ||||||
  CR | 27 (31%) | 17 (19.5%) | 12 (24.5%) | 10 (20.8%) | 8 (22.2%) | 13 (35.5%) |
  PR | 46 (52.9%) | 45 (51.5%) | 22 (44.9%) | 30 (62.5%) | 20 (55.6%) | 16 (43.2%) |
  CR + PR | 73 (83.9%) | 62 (71.3%) | 34 (69.4%) | 40 (83.3%) | 28 (77.8%) | 29 (78.4%) |